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Abstract
Background: Electroencephalographic (EEG) status epilepticus is described in 10 to 35% of patients with
postanoxic encephalopathy after successful cardiopulmonary resuscitation and is associated with case fatality rates
of 90 to 100%. It is unclear whether these EEG patterns represent a condition to be treated with anticonvulsants to
improve outcome, or an expression of severe ischemic damage, in which treatment is futile.
Methods/Design: TELSTAR is a multicenter clinical trial with two parallel groups, randomized treatment allocation,
open label treatment, and blinded endpoint evaluation (PROBE design). We aim to enroll 172 adult patients with
postanoxic encephalopathy and electroencephalographic status epilepticus after successful cardiopulmonary
resuscitation, admitted to the ICU, in whom continuous EEG monitoring is started within 24 hours after admission.
Patients are randomly assigned to either medical treatment to suppress all electrographic seizure activity, or no
treatment of electroencephalographic status epilepticus. Antiepileptic treatment is based on guidelines for
treatment of overt status epilepticus and is started within 3 hours after the diagnosis. If status epilepticus returns
during tapering of sedative medication after suppression of all epileptiform activity for 2 × 24 hours, it will be
considered refractory. The primary outcome measure is neurological outcome defined as the Cerebral Performance
Category (CPC) score at 3 months, dichotomized into ‘good’ (CPC 1 to 2 = no or moderate neurological disability)
and ‘poor’ (CPC 3 to 5 = severe disability, coma, or death). Secondary outcome measures include mortality and, for
patients surviving up to 12 months, cognitive functioning, health related quality of life, and depression.
Trial registration: Clinicaltrials.gov; NCT02056236. Date of registration: 4 February 2014.
Keywords: Cardiopulmonary resuscitation, Postanoxic encephalopathy, Electroencephalography, Status epilepticus,
Generalized periodic discharges, Anticonvulsants, Randomized controlled trial, Neurological outcome
Background
After successful cardiopulmonary resuscitation, 64 to
74% of patients remain unconscious at hospital arrival as
a result of diffuse postanoxic encephalopathy [1,2]. In
these patients, a spectrum of electroencephalographic
(EEG) changes can be observed, reflecting varying extents
of ischemic brain injury [3]. Electroencephalographic
status epilepticus is described in 10 to 35% [3-8] and is
strongly associated with poor outcome: case fatality was
90 to 100% in prospective case series, despite treatment
with anticonvulsants [4,6-10]. Without EEG monitoring,
approximately one in five cases remains undiscovered
due to the absence of clinical signs [6,11,12].
The diagnostic criteria for electroencephalographic
status epilepticus in comatose patients with postanoxic
encephalopathy are controversial [13,14]. The American
Clinical Neurophysiology Society defines unequivocal
seizures as generalized spike-wave discharges at 3 Hz or
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faster or clearly evolving discharges of any type at 4 Hz
or faster, either focal or generalized [15]. However, some
experts also consider other rhythmic or periodic patterns,
such as generalized or lateralized periodic discharges or
rhythmic delta activity as seizure activity [6,8].
It is unclear whether electroencephalographic seizure
patterns in patients with postanoxic encephalopathy
represent a condition which can be treated with anticon-
vulsants to improve patients’ outcome, or have to be
regarded as an expression of severe ischemic damage, in
which treatment with anticonvulsants would be futile
[16,17]. Case series suggest that in patients with electro-
encephalographic status epilepticus, preserved brainstem
reactions and EEG background reactivity are associated
with a favorable outcome [4]. It is unclear whether treat-
ment with anticonvulsants reduces the risk of a poor
outcome in these patients and if so, how intensive this
treatment should be. In the only prospective, non-
randomized intervention study, a stepwise treatment up
to pentobarbital-induced burst suppression resulted in a
good outcome for 6% of patients with clinically overt or
electroencephalographic status epilepticus [18]. This
proportion is approximately the same as reported in
observational studies, irrespective of treatment [4,6,8,9].
Despite the lack of evidence, most neurologists treat
status epilepticus in comatose patients after cardiopul-
monary resuscitation with anticonvulsants. Increased de-
tection of electroencephalographic status epilepticus by
continuous EEG monitoring has led to increased pre-
scription of these drugs [19,20]. However, treatment is
mostly moderately intensive. In The Netherlands, only
one third of physicians treat these patients equally inten-
sively as those with clinically overt status epilepticus
[21]. Both intensive antiepileptic treatment and no treat-
ment of electroencephalographic status epilepticus are
considered standard modalities, where some experts
believe that treatment is useless and others that it is
unethical to withhold it.
Apart from the intensity, the timing of treatment is
probably an important determinant of treatment effect.
Mechanisms such as excessive glutamate release are
known to worsen brain damage in ongoing status epilep-
ticus within 20 to 40 minutes, even without clinical signs
and despite good oxygenation [22]. Also, prolonged
duration of status epilepticus reduces the effect of
treatment; for example, due to receptor trafficking [23].
In approximately a quarter of patients, the electroen-
cephalographic status epilepticus starts within 24 hours
after cardiopulmonary resuscitation [5,10,12]. In pre-
vious studies, EEG monitoring started at a median
of 2 to 3 days after cardiopulmonary resuscitation, indi-
cating that diagnosis and subsequent treatment of elec-
troencephalographic status epilepticus started relatively
late [4,8].
We conclude that evidence for a beneficial effect of
medical treatment of electroencephalographic status
epilepticus in patients with postanoxic encephalopathy
after cardiopulmonary resuscitation is insufficient. To be
effective, treatment should be sufficiently intensive and
initiated as early as possible after the onset of status
epilepticus. Therefore, we aim to study the effect of
intensive and early medical treatment of electroencepha-
lographic status epilepticus on functional outcome of
comatose patients after cardiopulmonary resuscitation in
a randomized controlled clinical trial.
Hypothesis
Medical treatment of electroencephalographic status
epilepticus improves outcome of patients with posta-




TELSTAR is a multicenter clinical trial with two parallel
groups, randomized treatment allocation, open label
treatment and blinded endpoint evaluation (PROBE
design). The trial has been registered in the United
States National Institutes of Health Clinical Trials re-
gistry (clinicaltrials.gov, identifier NCT02056236) on 4
February 2014. The study population consists of coma-
tose adult patients after cardiopulmonary resuscitation,
admitted to the ICU, with electroencephalographic sta-
tus epilepticus on continuous EEG. Detailed eligibility
criteria are listed in Table 1.
Table 1 Eligibility criteria





A known history of another
medical condition with limited life
expectancy (<6 months)
Age 18 years or older Any progressive brain illness, such
as a brain tumor or
neurodegenerative disease
Continuous EEG with at least 8
electrodes started within 24 hours
after cardiopulmonary resuscitation
Pre-admission glasgow outcome
scale score of 3 or lower
Electroencephalographic status
epilepticus on continuous EEG
Reason other than neurological
condition to withdraw treatment
Informed consent given by a
legal representative
Follow-up impossible due to
logistic reasons, for example not
living in The Netherlands
Possibility to start treatment within
3 hours after detection of
electroencephalographic status
epilepticusa
Known participation in any
interventional study
aIf status epilepticus is present at initiation of continuous EEG, the starting time of
continuous EEG is considered as detection time. EEG = electroencephalography.
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Definitions of electroencephalographic status epilepti-
cus will be according to standardized critical care EEG
terminology [15]. They may consist of generalized spike-
wave discharges at 3 Hz or faster, clearly evolving dis-
charges of any type at 4 Hz or faster (either generalized
or focal), or periodic discharges (generalized or latera-
lized) at any frequency. For continuous seizure activity,
the minimum duration requirement is 30 minutes. Inter-
mittent seizures of 5 minutes and longer, recurring at
least twice, with seizure-free intervals shorter than 60 -
minutes will also be included. EEG assessment for inclu-
sion will ultimately be left to the discretion of the
treating neurologist or clinical neurophysiologist.
Informed consent
Written informed consent will be obtained from the
patient's authorized representative prior to the per-
formance of any protocol-specific procedure. Surviving
patients will be asked for informed consent for par-
ticipation and additional follow-up on long-term outcome.
Separate informed consent will be asked for neuropsy-
chological examination at 12 months, if applicable. The
study will be conducted according to the principles of
the Declaration of Helsinki (Seventh Revision, Fortaleza,
2013) and in accordance with the Dutch Medical
Research Involving Human Subjects Act (WMO) and
local guidelines.
Treatment allocation
All participating subjects receive standard best medical
management according to current guidelines, including
therapeutic hypothermia or controlled normothermia
with sedation for 24 hours. In addition, they will be
randomly assigned to either medical treatment or no
treatment of electroencephalographic status epilepticus.
In both groups, decisions regarding limitation or with-
drawal of treatment will be made in accordance with the
Dutch guidelines for postanoxic coma management [24].
Reasons for withdrawal of treatment will be documented.
Subjects will be randomized using ALEA (Clinical
Trial Center Maastricht, The Netherlands), which is an
online, central randomization service. To prevent imbal-
ance of allocated treatments, blocked randomization will
be used, with a 1:1 allocation, stratified by center, and
random block size ranging from 4 to 10 subjects.
Intervention group: treatment of electroencephalographic
status epilepticus
Since no treatment with anticonvulsants has been
proven superior to another, the choice of medication is
ultimately left to the discretion of the treating neurolo-
gist, based on local protocols. However, to prevent large
differences with respect to the intensity of treatment,
recommendations are made as displayed in Figure 1. In
summary, treatment consists of a stepwise approach,
from intermittent administration of antiepileptic drugs
up to treatment with barbiturates, in accordance with
international guidelines for treatment of overt status epi-
lepticus [25,26]. Each subsequent step is taken as soon
as possible when previous steps fail to suppress epilepti-
form activity. The treatment objective is to suppress all
epileptiform activity on the EEG during at least 24 hours.
Induction of burst suppression is not obligate. If the
status epilepticus returns after tapering sedative me-
dication, the treatment procedure will be repeated
during another 24 hours. If status epilepticus returns
after 2 × 24 hours, it is considered refractory. We accept
that treatment with barbiturates may lead to prolonged
hospitalization of several days due to their influence on
prognostic tests.
Control group: no treatment of electroencephalographic
status epilepticus
In this group, patients will be treated according to stand-
ard guidelines for treatment of comatose patients after
cardiopulmonary resuscitation, without EEG-based treat-
ment of status epilepticus. Treatment to suppress clinic-
ally manifest myoclonic jerks in this group, and in those
patients surviving beyond ICU discharge, is left to the
discretion of the treating physician.
Outcome assessment
The primary outcome measure is neurological outcome,
defined as the Cerebral Performance Category (CPC)
score at 3 months, dichotomized into ‘good’ (CPC 1 to
2 = no or moderate neurological disability) and ‘poor’
(CPC 3 to 5 = severe disability, coma, or death).
Secondary outcome measures include mortality, CPC
scores at 6 and 12 months, length of stay on the ICU,
duration of mechanical ventilation, and seizure recur-
rence rate within 12 months. In case of survival, add-
itional outcome measures include quality of life after a
year as measured by the Medical Outcomes Study 36-
item short-form health survey (SF-36) [27], depression
after a year as measured by the Montgomery and Åsberg
Depression Rating Scale (MADRS) [28], and cognitive
functioning after a year as measured by detailed neuro-
psychological examination. Secondary outcome measures
will not be collected to test between-group differences,
since the estimated number of survivors is small. These
measures will be collected to thoroughly assess outcome
and quality of life of survivors.
Additionally, a limited amount of data on the use of re-
sources will be collected for analysis of cost-effectiveness,
including place of residence at one year and admission
to hospitals, rehabilitation centers, and nursing homes
within the first year.
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Study procedures and data collection
For data collection and management, the OpenClinica
open source software (OpenClinica LLC and collabora-
tors, Waltham, MA, USA) will be used. At randomi-
zation, patients receive a study number by which all data
is coded. The trial coordinator and principal investigator
safeguard the key to this code.
Figure 2 shows the study flow chart. In participating
hospitals, continuous EEG monitoring is part of regular
patient care and is initiated as soon as possible after
admission to the ICU. In order to detect seizure activity
early, continuous EEG registrations are checked three-
hourly by a neurologist, clinical neurophysiologist, or
clinical neurophysiology technician. For practical rea-
sons, these checks will not take place regularly between
midnight and 8 am. When patients meet the eligibility
criteria and informed consent is obtained, they will be
randomly allocated to one of the treatment arms. It
is not possible to see the treatment allocation before
the patient is randomized and registered in the study
Figure 1 Stepwise treatment approach for electroencephalographic status epilepticus. Each consecutive treatment step is taken when
previous steps have failed to suppress electroencephalographic seizure activity. After 24 hours of treatment, sedative agents (thiopental, propofol,
and continuously administrated benzodiazepines) will be tapered and intermittently administrated antiepileptic drugs (phenytoin, valproic acid,
and levetiracetam) will be continued. If the status epilepticus returns, the treatment procedure will be repeated during another 24 hours. If status
epilepticus returns after 2 × 24 hours, it is considered refractory. EEG = Electroencephalography.
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database. Neither is it possible to withdraw the patient
from the database after treatment assignment. After
randomization, treating physicians and patients (or their
legal representatives) will be aware of the treatment
assignment.
Baseline data will be obtained at randomization and
include patient characteristics (age, sex, medical history,
use of anticonvulsants), pre-hospital factors (cause and
location of cardiac arrest, initial cardiac rhythm, time to
return of spontaneous circulation), clinical parameters
(Glasgow Coma Scale score, brain stem reflexes), electro-
encephalographic features (seizure pattern, background
reactivity), target temperature, and the Acute Physiology
and Chronic Health Evaluation (APACHE) score. During
admission on the ICU, daily neurological examinations
will be performed as part of regular care. Selected me-
dication for treatment of the status epilepticus will be
recorded. At ICU discharge or in case of mortality, the
duration of ventilation and duration of admission will be
assessed.
Follow-up will be done by means of a telephone in-
terview by a trained investigator or research nurse,
who is blinded for the allocated treatment. At 3, 6, and
12 months, CPC scores will be assessed. Place of resi-
dence, duration of admission in hospitals, rehabilitations
centers, or nursing homes, seizure recurrence rates, use
of anticonvulsants, and serious adverse events will be re-
corded. At 12 months, after obtaining separate informed
consent, quality of life, depression, and cognitive func-
tioning will be assessed in the local hospital.
Subjects can leave the study at any time for any reason
if they wish to do so without any consequences. Also,
the investigator can decide to withdraw a subject from
the study for urgent medical reasons. Subjects will be re-
placed after withdrawal for any reason. Every attempt
will be made to complete the primary follow-up in pa-
tients who are withdrawn from treatment.
Statistical considerations
The primary analysis will be a single comparison between
the treatment groups with regard to the primary outcome
measure at 3 months, according to the intention-to-treat
principle. To assess the effect of treatment with anticon-
vulsants, the absolute risk reduction of poor outcome will
be calculated, including the corresponding 95% confi-
dence interval. Baseline characteristics, raw distributions
of the CPC score, and scores of secondary outcome mea-
sures will first be presented in a descriptive way. For sec-
ondary outcome measures, between-group differences
will be analyzed by means of independent samples t-tests,
Mann–Whitney tests, or Fisher exact tests, where appro-
priate. If necessary, multivariate regression analysis will
be used to adjust for imbalances in main prognostic vari-
ables between the intervention and control groups.
Power calculations are hampered by the absence of
data from randomized trials. With a presumed reduction
of poor outcome from 99% to 92%, alpha of 5%, power
of 80%, and 1-tailed testing, 84 patients per treatment
group are needed to detect superiority of treatment with
anticonvulsants. An O’Brien Fleming interim analysis
will be performed after a total of 86 enrollments. If the
difference between the treatment groups at that time is
significant at P <0.00557, the trial will be stopped be-
cause of ‘proof beyond reasonable doubt’ that treatment
with anticonvulsants is superior to treatment without
anticonvulsants. To compensate for this interim analysis,
two additional patients per group will be included. This
indicates an intended sample size of 172 subjects.
With an estimated incidence of electroencephalo-
graphic status epilepticus of 20% in comatose patients
with postanoxic encephalopathy [3], 860 patients will
have to be monitored with continuous EEG. With five
Figure 2 Study flow chart. CPC = Cerebral Performance Category;
MADRS: Montgomery and Åsberg Depression Rating Scale; SF-36:
Medical Outcomes Study 36-item short-form health survey.
Ruijter et al. Trials 2014, 15:433 Page 5 of 8
http://www.trialsjournal.com/content/15/1/433
Dutch hospitals participating at the submission of this
manuscript, we estimate an enrollment period of four
and a half years.
Safety assessments
Medical treatment of electroencephalographic status
epilepticus may lower the high risk of death. The risk
of an increase of morbidity or mortality is considered
negligible. Otherwise, treatment may lead to prolonged
hospitalization of several days of comatose patients who
otherwise would have died. We assume this reasonable,
since both antiepileptic treatment and no treatment are
current standard modalities in these patients.
All adverse events reported by the investigator, staff,
or spontaneously by the subject will be recorded in the
electronic case record form. Adverse events are defined
as any undesirable experience occurring to a subject
during the clinical trial. A serious adverse event is
defined as any adverse event that results in death, a life-
threatening condition, inpatient hospitalization or pro-
longation of existing hospitalization, or persistent or
significant disability.
The trial is monitored by an independent Data Safety
Monitoring Board (DSMB). The DSMB is chaired by a
biostatistician and further includes an intensivist and a
neurologist. This committee will review data for safety
after every 43 enrolled patients from the study have had
their primary outcome measurement. Because of the ex-
pected high proportion of patients with a poor outcome
in the study population, and the consequent overlap be-
tween safety endpoints and the primary endpoint, the
evaluation of safety by the DSMB at that time will be
qualitative. Summary of key efficacy endpoints (primary
outcomes, mortality) will be provided for a planned
interim analysis after 86 enrollments.
Ethical approval
TELSTAR has received ethical approval from the Med-
ical Research Ethics Committee Twente (Dutch: METC
Twente) in December 2013 (reference: NL46296.044.13).
Publication of trial results
The trial results will be published by the members of the
Executive Committee, on behalf of the TELSTAR study
team. With 36 or more enrollments, local principle in-
vestigators of participating centers will be included in
the primary author list. Before submission of any manu-
script, all local principal investigators will have had the
opportunity to comment on the manuscript.
Discussion
We present a study protocol for a multicenter, random-
ized controlled trial to investigate treatment of electro-
encephalographic status epilepticus in patients with
postanoxic encephalopathy after cardiopulmonary resus-
citation. Both sides of the spectrum, for example, antiep-
ileptic treatment to burst suppression and no treatment
at all of electroencephalographic status epilepticus are
current standard modalities in these patients [19,21].
The benefits of antiepileptic treatment have never been
investigated in a randomized controlled trial.
The focus of debate is often whether EEG patterns
represent epileptic activity, that can be treated with anti-
convulsants to improve outcome, or not [13,14]. In the
only prospective case series of intensive antiepileptic
treatment in these patients, EEG patterns of enrolled
subjects were insufficiently reported [18]. In the current
trial, we include a broad range of possibly epileptiform
EEG patterns. However, with a clear definition of the
distinct eligible seizure patterns, based on standardized
EEG terminology [15], we aim to increase insight into
the effects of treatment in relation to specific patterns.
Although EEG analysis prior to patient enrollment will
be performed locally by the treating neurologist or clin-
ical neurophysiologist, all EEGs will also be analyzed off-
line by dedicated clinical neurophysiologists, to optimize
categorization of patterns.
If beneficial at all, the optimal duration of treatment of
status epilepticus in postanoxic encephalopathy is un-
clear. Previous studies suggest that in more than half of
cases the duration of seizure activity is less than
24 hours, and in more than three quarters of cases less
than 48 hours [5,12]. We consider ongoing status epilep-
ticus after suppression of all epileptiform activity for 2 ×
24 hours as refractory and argue that patients with on-
going seizure activity beyond this period are unlikely to
benefit from prolonged antiepileptic treatment.
In previous, non-randomized studies concerning treat-
ment of status epilepticus after cardiopulmonary resu-
scitation, diagnosis was either based on clinical signs
[29-31], or EEG seizure activity [6,8,10], or a combin-
ation of clinical and EEG findings [4,18]. However, myo-
clonic jerks are often suppressed by sedative medication.
Furthermore, myoclonia are often unrelated to EEG
findings. For most neurologists, the threshold to treat
patients with overt myoclonia is lower than for patients
with non-convulsive electroencephalographic seizures.
However, irreversible damage is probably even more
likely in patients with myoclonia, since the risk of poor
outcome is larger [4] and neuronal necrosis is more
common [17]. In the current study, the diagnosis of
status epilepticus is EEG-based, irrespective of clinical
signs.
Our study protocol intends to minimize time from on-
set of electroencephalographic status epilepticus to start
of treatment, as ongoing seizure activity may lead to
additional damage [22] and decreased effect of medica-
tion [23]. EEG monitoring will be started within
Ruijter et al. Trials 2014, 15:433 Page 6 of 8
http://www.trialsjournal.com/content/15/1/433
24 hours. Epileptic activity that is initially suppressed by
the anticonvulsive effects of hypothermia and sedative
medication will therefore be detected early. The max-
imum time of 3 hours since the diagnosis to obtain in-
formed consent and commence treatment is chosen
pragmatically.
Although the trial protocol contains clear recommen-
dations, including the intensity of antiepileptic treatment
in the intervention group, the diagnosis of electrographic
status epilepticus and the choice of specific anticonvul-
sive medication are ultimately left to the discretion of
the treating physician. Since we consider the pragmatic
character of this difficult trial very important, we accept
potentially detrimental effects of variations due to free-
dom of treatment. These include restricted extrapolation
resulting from differences between local protocols and
effect dilution resulting from treatment of overt myoclo-
nia with anticonvulsants in the control group.
Blinding of treating physicians for treatment allocation
is virtually impossible, as the administration of anti-
convulsants is guided by bedside EEG measurements.
However, outcome assessment of surviving patients is
performed blinded for the treatment allocation.
Concluding, this study will be the first to evaluate the
additional value of medical treatment of electroencepha-
lographic status epilepticus for patients after successful
cardiopulmonary resuscitation. Furthermore, it will pro-
vide clinical and electrographic characteristics for identi-
fying patients that might benefit from this treatment.
Trial status
Recruitment to TELSTAR started in May 2014, with 5
participating hospitals. Interested centers with ICU and
continuous EEG monitoring facilities are welcome to
participate.
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